Title:
アルツハイマー病に関係する生体分子
Document Type and Number:
Japanese Patent JP7241104
Kind Code:
B2
Abstract:
The invention relates to panels of biomarkers including proteins phosphatase 1 regulatory subunit 14A and/or 2′,3′-cyclic-nucleotide 3′-phosphodiesterase and/or phosphorylated tau or fragments thereof and methods using thereof for diagnosing, staging, treating and assessing the response of a treatment for a neurocognitive disorder characterised by tau toxicity, in particular for Alzheimer's disease. The present invention shows that the biomarkers disclosed herein are elevated in the brain of subjects with an advanced stage of a neurocognitive disorder (Braak stage V/VI) and/or are regulated in the CSF of AD subjects in comparison to cognitively affected non-AD controls; and/or regulated in response to two casein kinase 1 delta inhibitors.
More Like This:
| WO/2021/149329 | NOVEL USE OF HIC-5 INHIBITOR |
| WO/2020/201525 | MULTIFUNCTIONAL COMPOUNDS FOR POLYMER MATRIX GRAFTING |
| JPH03128393 | TREATMENT AND DIAGNOSIS OF HUMAN LYMPHOTROTROPIC NUTRITIVE VIRUS |
Inventors:
Ian Hugo Pique
Malcolm Andrew Ward
Claire Louise Russell
Vikram Mitra
Malcolm Andrew Ward
Claire Louise Russell
Vikram Mitra
Application Number:
JP2021005131A
Publication Date:
March 16, 2023
Filing Date:
January 15, 2021
Export Citation:
Assignee:
Electrophoretics Limited
International Classes:
G01N33/68; A61K31/13; A61K31/27; A61K31/404; A61K31/437; A61K31/4439; A61K31/445; A61K31/506; A61K31/55; A61K39/395; A61K45/00; A61P25/16; A61P25/28; A61P43/00
Domestic Patent References:
| JP2013121956A | ||||
| JP2002523461A | ||||
| JP2018510343A |
Foreign References:
| WO2011005893A2 |
Other References:
C.-X. Gong,Post-translational modifications of tau protein in Alzheimer’s disease,J Neural Transm,2005年,Vol.112,Page.813-838
C.-X. Gong,Hyperphosphorylation of Microtubule-Associated Protein Tau: A Promising Therapeutic Target for Alzheimer Disease,Curr Med Chem,2008年,Vol.15 No.23,Page.2321-2328
Thomas McAvoy,Quantification of Tau in Cerebrospinal Fluid by Immunoaffinity Enrichment and Tandem Mass Spectrometry,Clinical Chemistry,2014年,Vol.60 No.4,Page.683-689
Roman Vlkolinsky,Decreased brain levels of 29,39-cyclic nucleotide-39-phosphodiesterase in Down syndrome and Alzheimer’s disease,Neurobiology of Aging,2001年,Vol.22,Page.547-553
Michael Fountoulakis,Proteomics-driven progress in neurodegeneration research,Electrophoresis,2006年,Vol.27,Page.1556-1573
Matthew D Li,Integrated multi-cohort transcriptional meta-analysis of neurodegenerative diseases,Acta Neuropathologica Communications,2014年,Vol.2,Page.93
Christopher D Aluise,Peptides and proteins in plasma and cerebrosipinal fluid as biomarkers for the prediction, diagnosis, and monitoring of the therapeutic efficacy of Alzheimer's disease,Biochim Biophys Acta,2008年08月07日,Vol.1782 No.10,Page.549-558
Henrik Zetterberg,Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: More to Come?,Journal of Alzheimer’s Disease,2013年,Vol.33,Page.S361-S369
Sayuri Taniguchi-Watanabe,Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau,Acta Neuropathol,2015年11月04日,Vol.131,Page.267-280
高島明彦,認知症とタウ蛋白との関係,埼玉医科大学雑誌,2017年03月,Vol.43 No.2,Page.134-141
C.-X. Gong,Hyperphosphorylation of Microtubule-Associated Protein Tau: A Promising Therapeutic Target for Alzheimer Disease,Curr Med Chem,2008年,Vol.15 No.23,Page.2321-2328
Thomas McAvoy,Quantification of Tau in Cerebrospinal Fluid by Immunoaffinity Enrichment and Tandem Mass Spectrometry,Clinical Chemistry,2014年,Vol.60 No.4,Page.683-689
Roman Vlkolinsky,Decreased brain levels of 29,39-cyclic nucleotide-39-phosphodiesterase in Down syndrome and Alzheimer’s disease,Neurobiology of Aging,2001年,Vol.22,Page.547-553
Michael Fountoulakis,Proteomics-driven progress in neurodegeneration research,Electrophoresis,2006年,Vol.27,Page.1556-1573
Matthew D Li,Integrated multi-cohort transcriptional meta-analysis of neurodegenerative diseases,Acta Neuropathologica Communications,2014年,Vol.2,Page.93
Christopher D Aluise,Peptides and proteins in plasma and cerebrosipinal fluid as biomarkers for the prediction, diagnosis, and monitoring of the therapeutic efficacy of Alzheimer's disease,Biochim Biophys Acta,2008年08月07日,Vol.1782 No.10,Page.549-558
Henrik Zetterberg,Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: More to Come?,Journal of Alzheimer’s Disease,2013年,Vol.33,Page.S361-S369
Sayuri Taniguchi-Watanabe,Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau,Acta Neuropathol,2015年11月04日,Vol.131,Page.267-280
高島明彦,認知症とタウ蛋白との関係,埼玉医科大学雑誌,2017年03月,Vol.43 No.2,Page.134-141
Attorney, Agent or Firm:
Toru Ishikawa
Previous Patent: Information processing equipment
Next Patent: FILE STORAGE SYSTEM AND FILE MANAGEMENT METHOD BY FILE STORAGE SYSTEM
Next Patent: FILE STORAGE SYSTEM AND FILE MANAGEMENT METHOD BY FILE STORAGE SYSTEM